+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07694440

Evaluating the Safety, Tolerability, and Efficacy of MZE782 in Adults with Phenylketonuria Using Different Doses Compared to Placebo

Led by Maze Therapeutics · Updated on 2026-10-23

38

Participants Needed

9

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying MZE782 in adults with Phenylketonuria PKU to evaluate its safety, tolerability, and effectiveness. This Phase 2 trial is designed as a randomized, double-blind, placebo-controlled, dose-ranging study to assess how well MZE782 works and how safe it is for people aged 18 to 75 with PKU. Maze Therapeutics is leading this research to better understand treatment options for this condition. Participants will be assigned to groups receiving either low or high doses of MZE782 tablets or a placebo. Some groups may need to stop certain PKU medications before starting the study treatment. The study measures include changes in blood phenylalanine levels and drug concentrations over several weeks. The treatment period extends from baseline through Week 17, with specific assessments at Weeks 1, 2, 3, 4, 8, 10, 13, and 17. During the study, participants will undergo regular blood tests to monitor phenylalanine levels and drug concentrations. Safety will be closely observed by tracking any adverse events from Week 0 to Week 17. Participants must keep their diet and protein intake consistent and may have to stop some PKU medications according to group assignments. The total study duration for participants is up to about 17 weeks, including follow-up assessments.

CONDITIONS

Brief Title

A Study of MZE782 in Adults With PKU

Research Team

M

Maze Therapeutics

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here